SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
about
Interactions between kidney disease and diabetes: dangerous liaisonsBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisUnderstanding and overcoming metformin gastrointestinal intolerance.Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.The optimal target for acute glycemic control in critically ill patients: a network meta-analysis.Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UKAn Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.
P2860
Q26740630-129774D8-7C8D-4E59-A886-C8C6584BF7B4Q28553482-0FF9CF23-9D1F-4C90-A504-FCA732F7C03EQ30240030-251A85D8-92D4-4FB5-BDA3-2E31B0562B10Q33625207-D5423231-FE94-4610-A665-BBD758A82D9DQ37588847-75B5E8BB-9CD9-4F1B-8357-EA1A1840E2CFQ37672448-BE2078BC-370B-4857-A37E-70CD25BD6715Q37712199-418257C8-719C-4774-84DB-56F97634CE13Q38371417-95357411-895A-400A-B2C1-1D1EFB9AAE86Q38802437-3477088B-7876-4BBD-93F7-EFBC81C22A36Q38907817-F9034329-D8E9-4F51-960C-E996DB780DA1Q38936746-3036CF8E-A411-4E2A-B31C-4A0D42611759Q38968055-BD0277A3-FAA2-44D1-8641-2F27A70D4866Q39190208-6B887291-CF14-42F3-9D07-7E1265A201BCQ39231122-0C3CBD39-B069-479D-892C-FA00D2ECB55CQ39290337-3E49DCBC-9D26-455A-BA61-A8F9B9D9C61FQ41323535-3F27A57A-EF32-4DE9-B917-A4391C98247CQ42082791-0363BB98-CB69-4509-B0CA-3F47C5D3C6C2Q42371759-12AB97DB-18EA-44E3-8F13-28F4146BC63FQ47174001-E1974A89-2CBA-49FF-ABE0-763C97C991C5Q47236288-4992E60D-3DF3-4B72-873B-8265799EEDB9Q50145776-53C18635-9B6F-456E-9372-27EF9CE65E40Q51034590-9F98B1C0-5EAC-4D74-BB85-8BE6DCF15198Q52603694-C754E665-B952-49B9-9C68-85B35316D344
P2860
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@ast
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@en
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@nl
type
label
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@ast
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@en
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@nl
prefLabel
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@ast
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@en
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@nl
P2860
P31
P921
P3181
P1433
P1476
SGLT-2 receptor inhibitors for ...... view and network meta-analysis
@en
P2093
Deepson S Shyangdan
P2860
P304
P3181
P356
10.1136/BMJOPEN-2015-009417
P407
P5008
P577
2016-02-24T00:00:00Z